Transplacental passage of isradipine in the treatment of pregnancy-induced hypertension
(1993) In American Journal of Hypertension 6(3 Pt 2). p.110-111- Abstract
- The aim of this study was to assess the concentration of isradipine in maternal and fetal plasma, and in amniotic fluid under steady-state conditions. Eight women were treated with 5-mg isradipine tablets twice daily and eight women were given slow-release isradipine capsules (SRO) twice daily for hypertension in pregnancy. Blood and amniotic fluid sampling for analysis of drug concentration was performed at delivery. In the isradipine tablet group, maternal and fetal plasma levels were 788 +/- 701 pg/mL (mean +/- SD) and 270 +/- 90 pg/mL, respectively. The corresponding levels in the SRO-treated group were 463 +/- 217 pg/mL and 185 +/- 95 pg/mL, respectively. In the amniotic fluid, the concentration was 74 +/- 42 pg/mL in the tablet group... (More)
- The aim of this study was to assess the concentration of isradipine in maternal and fetal plasma, and in amniotic fluid under steady-state conditions. Eight women were treated with 5-mg isradipine tablets twice daily and eight women were given slow-release isradipine capsules (SRO) twice daily for hypertension in pregnancy. Blood and amniotic fluid sampling for analysis of drug concentration was performed at delivery. In the isradipine tablet group, maternal and fetal plasma levels were 788 +/- 701 pg/mL (mean +/- SD) and 270 +/- 90 pg/mL, respectively. The corresponding levels in the SRO-treated group were 463 +/- 217 pg/mL and 185 +/- 95 pg/mL, respectively. In the amniotic fluid, the concentration was 74 +/- 42 pg/mL in the tablet group and 45 +/- 14 pg/mL in the SRO group. Therefore, isradipine passes the placental barrier, but its concentration is considerably lower in the fetal compartments. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1107602
- author
- Lunell, N O ; Bondesson, U ; Grunewald, C ; Ingemarsson, Ingemar LU ; Nisell, H and Wide-Swensson, Dag LU
- organization
- publishing date
- 1993
- type
- Contribution to journal
- publication status
- published
- subject
- in
- American Journal of Hypertension
- volume
- 6
- issue
- 3 Pt 2
- pages
- 110 - 111
- publisher
- Oxford University Press
- external identifiers
-
- pmid:8466718
- scopus:0027534499
- ISSN
- 1941-7225
- language
- English
- LU publication?
- yes
- id
- fc59f2d2-a4b9-45a1-a38d-7778a7dffd2f (old id 1107602)
- date added to LUP
- 2016-04-01 12:09:05
- date last changed
- 2021-01-03 06:45:20
@article{fc59f2d2-a4b9-45a1-a38d-7778a7dffd2f, abstract = {{The aim of this study was to assess the concentration of isradipine in maternal and fetal plasma, and in amniotic fluid under steady-state conditions. Eight women were treated with 5-mg isradipine tablets twice daily and eight women were given slow-release isradipine capsules (SRO) twice daily for hypertension in pregnancy. Blood and amniotic fluid sampling for analysis of drug concentration was performed at delivery. In the isradipine tablet group, maternal and fetal plasma levels were 788 +/- 701 pg/mL (mean +/- SD) and 270 +/- 90 pg/mL, respectively. The corresponding levels in the SRO-treated group were 463 +/- 217 pg/mL and 185 +/- 95 pg/mL, respectively. In the amniotic fluid, the concentration was 74 +/- 42 pg/mL in the tablet group and 45 +/- 14 pg/mL in the SRO group. Therefore, isradipine passes the placental barrier, but its concentration is considerably lower in the fetal compartments.}}, author = {{Lunell, N O and Bondesson, U and Grunewald, C and Ingemarsson, Ingemar and Nisell, H and Wide-Swensson, Dag}}, issn = {{1941-7225}}, language = {{eng}}, number = {{3 Pt 2}}, pages = {{110--111}}, publisher = {{Oxford University Press}}, series = {{American Journal of Hypertension}}, title = {{Transplacental passage of isradipine in the treatment of pregnancy-induced hypertension}}, volume = {{6}}, year = {{1993}}, }